[96a5a0]: / output / allTrials / identified / NCT00582920_identified.json

Download this file

298 lines (298 with data), 13.5 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
{
"info": {
"nct_id": "NCT00582920",
"official_title": "Investigation of Changes in Bone Scan Imaging Before and After Intravenous Bisphosphonate Therapy for Osseous Metastases From Breast Cancer",
"inclusion_criteria": "* Patients receiving intravenous biphosphonate therapy (zoledronic acid 4 mg or renal dose equivalent) as part of their treatment regimen, who are diagnosed with metastatic breast cancer involving surrounding bone.\n* Patients must have had prior treatment zoledronic acid (4 mg or adjusted dose for renal function) within 8 weeks.\n* The patients clinical status as assessed by a treating physician must be deemed appropriate for continuing treatment with zoledronic acid\n* The patient's clinical status, as assessed by a treating physician, must be deemed appropriate for an evaluation with a bone scan\n* The patient's medical status as assessed by a treating physician must be medically appropriate to receive zoledronic acid within the study time frame and in association with the study bone scan\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years\nMust have maximum age of 110 Years",
"exclusion_criteria": "* No evidence of bone metastases, or less than 3 osseous lesions felt to be consistent with bone metastases, on most recent bone scan performed for clinical indications prior to study entry.\n* Patients with illnesses, or conditions that would prevent them from understanding the nature of the study and complying with the protocol requirements",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Patients receiving intravenous biphosphonate therapy (zoledronic acid 4 mg or renal dose equivalent) as part of their treatment regimen, who are diagnosed with metastatic breast cancer involving surrounding bone.",
"criterions": [
{
"exact_snippets": "Patients receiving intravenous biphosphonate therapy",
"criterion": "intravenous biphosphonate therapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "zoledronic acid 4 mg or renal dose equivalent",
"criterion": "zoledronic acid dosage",
"requirements": [
{
"requirement_type": "dosage",
"expected_value": [
"4 mg",
"renal dose equivalent"
]
}
]
},
{
"exact_snippets": "diagnosed with metastatic breast cancer",
"criterion": "metastatic breast cancer",
"requirements": [
{
"requirement_type": "diagnosis",
"expected_value": true
}
]
},
{
"exact_snippets": "involving surrounding bone",
"criterion": "bone involvement",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Patients must have had prior treatment zoledronic acid (4 mg or adjusted dose for renal function) within 8 weeks.",
"criterions": [
{
"exact_snippets": "Patients must have had prior treatment zoledronic acid",
"criterion": "prior treatment with zoledronic acid",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "(4 mg or adjusted dose for renal function)",
"criterion": "dose of zoledronic acid",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": [
"4 mg",
"adjusted dose for renal function"
]
}
]
},
{
"exact_snippets": "within 8 weeks",
"criterion": "time since prior treatment with zoledronic acid",
"requirements": [
{
"requirement_type": "time frame",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 8,
"unit": "weeks"
}
]
}
}
]
}
]
},
{
"line": "* The patients clinical status as assessed by a treating physician must be deemed appropriate for continuing treatment with zoledronic acid",
"criterions": [
{
"exact_snippets": "The patients clinical status ... must be deemed appropriate for continuing treatment with zoledronic acid",
"criterion": "clinical status",
"requirements": [
{
"requirement_type": "appropriateness for treatment",
"expected_value": "appropriate for continuing treatment with zoledronic acid"
}
]
}
]
},
{
"line": "* The patient's clinical status, as assessed by a treating physician, must be deemed appropriate for an evaluation with a bone scan",
"criterions": [
{
"exact_snippets": "The patient's clinical status, as assessed by a treating physician, must be deemed appropriate for an evaluation with a bone scan",
"criterion": "clinical status",
"requirements": [
{
"requirement_type": "appropriateness for evaluation",
"expected_value": true
}
]
}
]
},
{
"line": "* The patient's medical status as assessed by a treating physician must be medically appropriate to receive zoledronic acid within the study time frame and in association with the study bone scan",
"criterions": [
{
"exact_snippets": "The patient's medical status as assessed by a treating physician must be medically appropriate to receive zoledronic acid",
"criterion": "medical status",
"requirements": [
{
"requirement_type": "appropriateness",
"expected_value": "medically appropriate to receive zoledronic acid"
}
]
},
{
"exact_snippets": "within the study time frame",
"criterion": "study time frame",
"requirements": [
{
"requirement_type": "association",
"expected_value": "within the study time frame"
}
]
},
{
"exact_snippets": "in association with the study bone scan",
"criterion": "study bone scan",
"requirements": [
{
"requirement_type": "association",
"expected_value": "in association with the study bone scan"
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must be FEMALE",
"criterions": [
{
"exact_snippets": "Must be FEMALE",
"criterion": "gender",
"requirements": [
{
"requirement_type": "expected_value",
"expected_value": "female"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
},
{
"line": "Must have maximum age of 110 Years",
"criterions": [
{
"exact_snippets": "maximum age of 110 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 110,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* No evidence of bone metastases, or less than 3 osseous lesions felt to be consistent with bone metastases, on most recent bone scan performed for clinical indications prior to study entry.",
"criterions": [
{
"exact_snippets": "No evidence of bone metastases",
"criterion": "bone metastases",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "less than 3 osseous lesions ... consistent with bone metastases",
"criterion": "osseous lesions",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": "<",
"value": 3,
"unit": "N/A"
}
}
]
}
]
},
{
"line": "* Patients with illnesses, or conditions that would prevent them from understanding the nature of the study and complying with the protocol requirements",
"criterions": [
{
"exact_snippets": "illnesses, or conditions that would prevent them from understanding the nature of the study",
"criterion": "cognitive ability",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "illnesses, or conditions that would prevent them from ... complying with the protocol requirements",
"criterion": "ability to comply with protocol",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}